Orion PharmaDHA:ORIONPHARM +3.02%71 OCF Margin % is 22.92% as of Mar. 2026, which is 3% above its 10-year median of 22.34. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 71/100 and a GF Value™ of BDT20.19 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 418 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 50.48% on this metric.
The historical rank and industry rank for Orion Pharma's OCF Margin % or its related term are showing as below:
DHA:ORIONPHARM'
s OCF Margin % Range Over the Past 10 Years
Min: 12.02 Med: 22.34 Max: 30.56
Current: 21.86
During the past 12 years, the highest OCF Margin % of Orion Pharma was 30.56%. The lowest was 12.02%. And the median was 22.34%.
DHA:ORIONPHARM's OCF Margin % is ranked worse than 50.48% of 418
companies
in the Utilities - Independent Power Producers industry
Industry Median: 21.975
vs DHA:ORIONPHARM: 21.86
Orion Pharma OCF Margin % Related Terms
Orion Pharma OCF Margin % Historical Data
* Premium members only.
The historical data trend for Orion Pharma's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: OCF Margin % Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma OCF Margin % vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Orion Pharma's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a OCF Margin % of 22.92% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Orion Pharma and its competitors. This is near median its historical median of 22.34. Over the past decade, Orion Pharma's OCF Margin % has ranged from 12.02 to 30.56. According to the industry distribution chart, Orion Pharma ranks #211 out of 418 companies in the Utilities - Independent Power Producers industry, placing it in the top 50.5%.
Is Orion Pharma's OCF Margin % too high?
Orion Pharma's current OCF Margin % of 22.92% is near median its 10-year median of 22.34. Over the past 10 years, this metric has ranged from a low of 12.02 to a high of 30.56. The Utilities - Independent Power Producers industry median OCF Margin % is 21.98. Orion Pharma's value of 22.92% is 4.3% above this industry median. Based on the distribution chart, Orion Pharma ranks #211 out of 418 companies in the Utilities - Independent Power Producers industry, which is below the industry midpoint. Overall, Orion Pharma has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's OCF Margin % compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #211 out of 418 companies for OCF Margin %. This places Orion Pharma in the lower half of its industry. The industry median OCF Margin % is 21.98. Orion Pharma's value of 22.92% is 4.3% above this benchmark. Historically, Orion Pharma's own OCF Margin % has ranged from 12.02 to 30.56 over the past decade. While the company's 10-year median is 22.34 vs. the industry median of 21.98, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for an Utilities - Independent Power Producers company?
The median OCF Margin % among Utilities - Independent Power Producers companies is 21.98, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current OCF Margin % of 22.92% is 4.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median OCF Margin % is 21.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current OCF Margin % is 22.92%, which is near median its own 10-year median of 22.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.19, compared to a current price of BDT30.70 — trading 52.1% above its estimated fair value. The current OCF Margin % is 22.92%, which is near median its 10-year median of 22.34 and 4.3% above the Utilities - Independent Power Producers industry median of 21.98. Orion Pharma's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current OCF Margin % is 22.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT30.70 is trading 52.1% above its estimated GF Value™ of BDT20.19.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
OCF Margin %: 22.92% (near median its 10-year median of 22.34)
GF Value™: BDT20.19 vs. price of BDT30.70 (52.1% above fair value)
Industry Position: 4.3% above the Utilities - Independent Power Producers median (#211 of 418)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
71GF Score
Get the complete analysis for DHA:ORIONPHARM
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
